👋 ¡Hola, Esplugues de Llobregat! We are excited to announce a major milestone for QIAstat-Dx: the development of a new state-of-the-art site in Esplugues de Llobregat, Barcelona to drive growth in infectious disease and precision medicine testing. Learn more 👉 https://lnkd.in/eRfJ-CzG ✅ Our new Barcelona site will drive the global expansion of QIAstat-Dx as QIAGEN strengthens its local presence with a multi-year investment. ✅ This new site will serve as an innovation hub for QIAstat-Dx, supporting the development of infectious disease tests and precision medicine applications.
关于我们
QIAGEN is the leading global provider of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies make these biomolecules visible and ready for analysis. Bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. Automation solutions tie these together in seamless and cost-effective workflows. QIAGEN provides solutions to more than 500,000 customers around the world in Molecular Diagnostics (human healthcare) and Life Sciences (academia, pharma R&D and industrial applications, primarily forensics). As of December 31 2021 QIAGEN employed more than 6,000 people in over 35 locations worldwide. Further information can be found at www.qiagen.com.
- 所属行业
- 生物技术研究
- 规模
- 5,001-10,000 人
- 总部
- Venlo，Limburg
- 类型
- 上市公司
- 领域
- Life science research、Molecular diagnostics、Applied testing (forensics, food safety testing, veterinary medicine)、Pharmaceutical research和bioinformatics
地点
凯杰员工
动态
-
Biomarkers such as EGFR, ALK, and KRAS have become essential tools in detecting and guiding the treatment of certain cancers. However, testing for these markers is often inconsistent among NSCLC patients, meaning not all patients receive the same level of access to testing or treatments. Watch lung cancer survivor and patient advocate, Terri Conneran, discuss this issue and the empowerment that comes with access to these tests. Check out our web page for more lung cancer resources 👉 https://lnkd.in/ePWwigqd #NSCLC #BiomarkerTesting #KRAS #LungCancer #LungCancerAwarenessMonth
-
QuantiFERON-TB Gold Plus helps fight the TB epidemic: Early diagnosis provides the best chance at preventing TB deaths. Last week, we asked you which infectious disease caused the most deaths in 2023. The answer: Tuberculosis (TB). New WHO data showed that 10.8 million people were infected with TB last year – the highest since WHO started tracking TB. TB claimed about 1.25 million lives. However, thanks to global efforts, the gap between incident TB cases and diagnosed cases narrowed. About 2.7 million cases went undiagnosed last year – down from a peak of 4 million during the height of the COVID-19 pandemic. By identifying TB infection with QuantiFERON-TB Gold Plus, doctors can provide targeted treatment of high-risk patients before they develop the contagious and often deadly active TB disease. Learn more about our fight to #EndTB with QuantiFERON-TB Gold Plus. 👉 https://lnkd.in/eV87s8hG #GlobalHealth #PublicHealth #QIAGEN
-
🎗️ November is lung cancer awareness month, a time to reconfirm our commitment to tackling the world’s no. 1 cancer killer. ✅ Genomic testing is becoming ever-more important as we work towards precision medicine for non-small cell lung cancer. 🤝 Let’s work together to deliver more insights in NSCLC testing and treatment. Learn more 👉 https://lnkd.in/e2n2d_jP
此处无法显示此内容
在领英 APP 中访问此内容等
-
Imagine a day when a blood-based test can identify prostate cancer patients who stop responding to first-line treatment in real time. Amin El-Heliebi, PhD, at the Medical University of Graz, Austria, is advancing research in this area, hoping that early intervention can help save more lives. Learn how this promising liquid biopsy research could transform prostate cancer treatment by enabling timely intervention.👉 https://lnkd.in/g7d9SBMq
-
-
🤔 Ever wonder what sustainability looks like in biotech? ✅ At QIAGEN, it means transforming every step of our process for a greener world. From electric fleets in the U.S. and Europe to launching QIAwave, our first eco-friendly product line, we’re working to make science sustainable. 🙌 It’s not just about where we’re going but how we get there. Here’s to a cleaner, brighter future in biotech!
-
✨ We are excited to announce our collaboration with McGill University to advance microbiome research and generate evidence-based knowledge for medicine and public health. Learn more 👉 https://lnkd.in/eevixJF2 ✅ This three-year partnership will drive microbiome science—the study of communities of microorganisms that live together in various environments, including the human body. ✅ McGill University will serve as a beta-testing site for new QIAGEN microbiome solutions. ✅ This partnership strengthens our commitment to microbiome research and supports innovation at the McGill Centre for Microbiome Research.
-
-
🤔 Antibiotics for viral respiratory infections? It seems counterintuitive. But it’s surprisingly common – and a big driver of antibiotic resistance. Practicing good antimicrobial stewardship starts with choosing the right test for your patient. But how do you choose? Here’s what we suggest: ⚠️ For high-risk patients: Our comprehensive QIAstat-Dx Respiratory Panel Plus. This extended panel tests for 18 viruses and 3 bacteria, giving you significant coverage of circulating pathogens. 🚶 For low-risk patients: Hone in on five of the most prevalent viruses with our QIAstat-Dx Respiratory Panel Mini. ✅ Learn more about how our family of QIAstat-Dx respiratory panel tests can help: https://lnkd.in/eztPrazn
-
We exceeded our outlook and delivered a solid performance in Q3 2024. Learn more 👉 https://lnkd.in/eZ3CHdXZ ◾ Q3 2024: Net sales of $502 million (+5% actual rates, +6% constant exchange rates, CER); diluted EPS of $0.44 and adjusted diluted EPS of $0.57. ➡ Net sales of $502 million CER ahead of outlook for at least $495 million CER and adjusted diluted EPS of $0.58 CER ahead of outlook for at least $0.55 CER. ➡ +10% CER growth in Diagnostic solutions leads results among product groups. ➡ 29.6% adj. operating income margin up 3 percentage points vs. 26.6% in Q3 2023. ➡ Free cash flow up 73% to $364 million in first nine months of 2024 vs. same 2023 period. ◾ FY 2024 net sales outlook reaffirmed for at least $1.985 billion CER on solid core business trends; adj. diluted EPS outlook increased to at least $2.19 CER.
-